Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Hereditary Cancer in Clinical Practice
|
January 18, 2019
Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes
Leslie Bucheit, Katherine Johansen Taber, Kaylene Ready
Prenatal Diagnosis
|
January 9, 2023
Expanded carrier screening: What conditions should we screen for?
James D Goldberg, Summer Pierson, Katherine Johansen Taber
Expert Review of Molecular Diagnostics
|
April 19, 2021
Fetal screening and whole genome sequencing: where are the limits?
Susan Hancock, Katherine Johansen Taber, James D Goldberg
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
June 21, 2019
Correction: Inaccuracies and shortcomings in "Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations"
Katherine Johansen Taber, Carrie Haverty, Susan Hancock, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
June 4, 2019
Inaccuracies and shortcomings in "Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations"
Katherine Johansen Taber, Carrie Haverty, Susan Hancock, et al.
Molecular Genetics & Genomic Medicine
|
November 7, 2019
Fragile X syndrome carrier screening accompanied by genetic consultation has clinical utility in populations beyond those recommended by guidelines
Katherine Johansen Taber, Jeraldine Lim-Harashima, Harris Naemi, et al.
The Application of Clinical Genetics
|
April 22, 2026
Outcomes and Management of Pregnancies Screening Positive for Microdeletions 22q11.2, 15q11.2, 1p36, 4p, or 5p: A Retrospective Cohort Study
D Claire Miller, Devika Chawla, Summer Pierson, et al.
Obstetrics and Gynecology
|
May 21, 2026
Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6-9 Weeks of Gestation
Lorraine Dugoff, Brent Mabey, Jhett Bordwell, et al.
Cancer
|
November 5, 2019
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
Valentina Vysotskaia, K Eerik Kaseniit, Leslie Bucheit, et al.
European Journal of Breast Health
|
April 9, 2026
Cancer Risk Assessment and Hereditary Cancer Genetic Testing in a Community OBGYN Setting
Edith Smith, Logan Schneider, Lauren Lenz, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Hereditary Cancer in Clinical Practice
|
January 18, 2019
Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes
Leslie Bucheit, Katherine Johansen Taber, Kaylene Ready
Prenatal Diagnosis
|
January 9, 2023
Expanded carrier screening: What conditions should we screen for?
James D Goldberg, Summer Pierson, Katherine Johansen Taber
Expert Review of Molecular Diagnostics
|
April 19, 2021
Fetal screening and whole genome sequencing: where are the limits?
Susan Hancock, Katherine Johansen Taber, James D Goldberg
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
June 21, 2019
Correction: Inaccuracies and shortcomings in "Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations"
Katherine Johansen Taber, Carrie Haverty, Susan Hancock, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
June 4, 2019
Inaccuracies and shortcomings in "Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations"
Katherine Johansen Taber, Carrie Haverty, Susan Hancock, et al.
Molecular Genetics & Genomic Medicine
|
November 7, 2019
Fragile X syndrome carrier screening accompanied by genetic consultation has clinical utility in populations beyond those recommended by guidelines
Katherine Johansen Taber, Jeraldine Lim-Harashima, Harris Naemi, et al.
The Application of Clinical Genetics
|
April 22, 2026
Outcomes and Management of Pregnancies Screening Positive for Microdeletions 22q11.2, 15q11.2, 1p36, 4p, or 5p: A Retrospective Cohort Study
D Claire Miller, Devika Chawla, Summer Pierson, et al.
Obstetrics and Gynecology
|
May 21, 2026
Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6-9 Weeks of Gestation
Lorraine Dugoff, Brent Mabey, Jhett Bordwell, et al.
Cancer
|
November 5, 2019
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
Valentina Vysotskaia, K Eerik Kaseniit, Leslie Bucheit, et al.
European Journal of Breast Health
|
April 9, 2026
Cancer Risk Assessment and Hereditary Cancer Genetic Testing in a Community OBGYN Setting
Edith Smith, Logan Schneider, Lauren Lenz, et al.
Page
of 3